These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10778993)

  • 1. Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence of lonidamine.
    Fanciulli M; Bruno T; Giovannelli A; Gentile FP; Di Padova M; Rubiu O; Floridi A
    Clin Cancer Res; 2000 Apr; 6(4):1590-7. PubMed ID: 10778993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells.
    Fanciulli M; Valentini A; Bruno T; Citro G; Zupi G; Floridi A
    Oncol Res; 1996; 8(3):111-20. PubMed ID: 8823807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correspondence re: M. Fanciulli et al., Energy metabolism of human LoVo colon carcinoma cells: correlation to drug resistance and influence fo lonidamine. Clin. Cancer Res., 6: 1590-1597, 2000.
    Kaplan O
    Clin Cancer Res; 2000 Oct; 6(10):4166-7. PubMed ID: 11051272
    [No Abstract]   [Full Text] [Related]  

  • 4. Glucose metabolism in adriamycin-sensitive and -resistant LoVo human colon carcinoma cells.
    Fanciulli M; Bruno T; Castiglione S; Del Carlo C; Paggi MG; Floridi A
    Oncol Res; 1993; 5(9):357-62. PubMed ID: 8038456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
    Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
    Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracellular P-glycoprotein in multidrug resistant tumor cells.
    Arancia G; Molinari A; Calcabrini A; Meschini S; Cianfriglia M
    Ital J Anat Embryol; 2001; 106(2 Suppl 1):59-68. PubMed ID: 11729998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods.
    Yang LY; Trujillo JM
    Cancer Res; 1990 Jun; 50(11):3218-25. PubMed ID: 2334917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells.
    Floridi A; Paggi MG; D'Atri S; De Martino C; Marcante ML; Silvestrini B; Caputo A
    Cancer Res; 1981 Nov; 41(11 Pt 1):4661-6. PubMed ID: 7306982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A search for multidrug resistance modulators: the effects of retinoids in human colon carcinoma cells.
    Bartolini G; Orlandi M; Papi A; Ammar K; Guerra F; Ferreri AM; Rocchi P
    In Vivo; 2006; 20(6A):729-33. PubMed ID: 17203756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Energy metabolism of adriamycin-sensitive and -resistant Ehrlich ascites tumor cells.
    Miccadei S; Fanciulli M; Bruno T; Paggi MG; Floridi A
    Oncol Res; 1996; 8(1):27-35. PubMed ID: 8704284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between multidrug resistance in human colon carcinoma LoVo/Adr cell line and intracellular calcium ion concentration].
    Ma Q; Zhang ZS; Zhang YL; Lai ZS
    Ai Zheng; 2002 Aug; 21(8):846-9. PubMed ID: 12478890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells.
    Scala S; Pacelli R; Iaffaioli RV; Normanno N; Pepe S; Frasci G; Genua G; Tsuruo T; Tagliaferri P; Bianco AR
    Cancer Res; 1991 Sep; 51(18):4898-902. PubMed ID: 1893380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further characterization of two distinct adriamycin-resistant sublines from LoVo human colon carcinoma cells.
    Yang LY; Trujillo JM; Su YZ
    Anticancer Res; 1992; 12(2):473-9. PubMed ID: 1349796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism.
    Floridi A; Bruno T; Miccadei S; Fanciulli M; Federico A; Paggi MG
    Biochem Pharmacol; 1998 Oct; 56(7):841-9. PubMed ID: 9774146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondria, hexokinase and pyruvate kinase isozymes in the aerobic glycolysis of tumor cells.
    Petrucci D; Cesare P; Colafarina S
    Ital J Biochem; 1997 Sep; 46(3):131-41. PubMed ID: 9442422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
    Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
    Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment and post-treatment with lonidamine in human colon carcinoma HT-29 cell line].
    Fuchs AG
    Medicina (B Aires); 2008; 68(1):13-22. PubMed ID: 18416315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth inhibition by rhein and lonidamine of human glioma cells in vitro.
    Floridi A; Gentile FP; Bruno T; Castiglione S; Zeuli M; Benassi M
    Anticancer Res; 1990; 10(6):1633-6. PubMed ID: 2285235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts.
    Ramachandran C; Wellham LL
    Anticancer Res; 2003; 23(3B):2681-90. PubMed ID: 12894558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.